Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 10/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11483337 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL11111116 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL8943722 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL15844402 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL8930349 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL2452782 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL5495850 | 0.98 | SOAT1 (0.42) | SOAT1PTGS2PLK1CYSLTR2CYSLTR1 | |
| SCHEMBL310860 | 0.94 | SOAT1 (0.39) | SOAT1PTGS2S100A4NPC1RAB9A | |
| SCHEMBL11485815 | 0.89 | EPHX2 (0.46) | SOAT1PTGS2 | |
| SCHEMBL310210 | 0.86 | SOAT1 (0.36) | SOAT1PTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-20140183414-A1 | POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8093349-B2 | Terminally modified polybranched polyimide, metal-plated terminally modified polybranched polyimide, and method for producing the same | UBE INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20100009206-A1 | TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, METAL-PLATED TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, AND METHOD FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-0375387-A2 | Amide compounds | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4906662-A | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0263229-A1 | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | SOAT1 3414/4885PTGS2 105/4885PLK1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.